Global Angiotensin Converting Enzyme (ACE) Inhibitors Market , By Product Type (Dicarboxylate-Containing Agents, Phosphonate-Containing Agents, Sulfhydryl-Containing Agents), Drug (Lisinopril, Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril, Others), Dosage Form (Oral Tablets, Oral Solution), Application (Heart Failure, Hypertension, Diabetes, Heart Attack, Chronic Kidney Disease, Others), Distribution Channel (Retail Pharmacy, Hospital Pharmacy, E-Commerce Websites, Online Drug Stores) – Industry Trends and Forecast to 2030.
Angiotensin Converting Enzyme (ACE) Inhibitors Market Analysis and Size
The rapidly increasing incidence of cardiovascular diseases is amongst the essential factors intensifying the growth and demand of angiotensin converting enzyme (ACE) inhibitors market. In addition, rise in prevalence of high blood pressure is also contributing to rising in the global market. The growing risk of developing high blood pressure and cardiovascular disorders due to the changing lifestyle is also the key factor flourishing angiotensin converting enzyme (ACE) inhibitors market.
Data Bridge Market Research analyses that the Angiotensin Converting Enzyme (ACE) inhibitors market which was USD 3,456.27 million in 2022, would rocket up to USD 9,520.26 million by 2030, and is expected to undergo a CAGR of 4.9% during the forecast period. This indicates that the market value. “dicarboxylate-containing agents” dominates the product type segment of the Angiotensin Converting Enzyme (ACE) Inhibitors Market owing to the growing demand for these types of containing agents. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Angiotensin Converting Enzyme (ACE) Inhibitors Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2014-2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product Type (Dicarboxylate-Containing Agents, Phosphonate-Containing Agents, Sulfhydryl-Containing Agents), Drug (Lisinopril, Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril, Others), Dosage Form (Oral Tablets, Oral Solution), Application (Heart Failure, Hypertension, Diabetes, Heart Attack, Chronic Kidney Disease, Others), Distribution Channel (Retail Pharmacy, Hospital Pharmacy, E-Commerce Websites, Online Drug Stores)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Novartis AG (Switzerland), Pfizer Inc. (U.S.), Merck & Co. (U.S.), AstraZeneca (UK), Sanofi (France), Boehringer Ingelheim (Germany), GlaxoSmithKline (U.K.), Teva Pharmaceutical Industries Ltd. (Israel), Lupin Limited (India), Cipla (India)., Torrent Pharmaceuticals Ltd. (India), Sun Pharmaceutical Industries Ltd. (India), Dr. Reddy's Laboratories Ltd. (India), Cadila Healthcare Limited (India), Macleods Pharmaceuticals Limited (India), Zydus Cadila (India), Mylan (US), Sandoz (Germany), Accord Healthcare (U.K.), Apotex (Canada)
|
|
Market Opportunities
|
|
Market Definition
ACE inhibitors are medications used to treat and manage hypertension, which is a significant risk factor for coronary disease, heart failure, stroke, and a host of other cardiovascular conditions. Most cases are primary and not attributable to any specific etiology.
Angiotensin Converting Enzyme (ACE) Inhibitors Market Dynamics
Drivers
- Rising incidences of cardiovascular diseases
Growing prevalence of cardiovascular diseases is amongst the essential factors intensifying the growth and demand of angiotensin converting enzyme (ACE) inhibitors market. This in turn has carved the way for the growth of the market.
- Research and development proficiencies
Rising expenditure for research and development proficiencies especially in the developed and developing economies pertaining to the medical instruments and devices will further create lucrative market growth opportunities. Research and development proficiencies being conducted to develop the medical instruments is also bolstering the market growth rate.
Opportunity
- Growing investment for healthcare facilities
Surging focus towards improving the condition of healthcare facilities and improving the overall healthcare infrastructure is another important factor fostering the growth of the market. Rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities.
Restraints/Challenges
- High cost associated with the research and development proficiencies
High cost associated with the research and development proficiencies, limited infrastructural facilities, products and dearth of awareness in the backward economies are expected to obstruct market growth. Also, lack of favorable reimbursement scenario and technology penetration in the developing economies, and lack of suitable infrastructure in low- and middle-income countries are projected to challenge the market in the forecast period of 2023-2030.
This Angiotensin Converting Enzyme (ACE) inhibitors market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Angiotensin Converting Enzyme (ACE) Inhibitors Market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
-
In May 2021, Novartis announced that it had received FDA approval for its new ACE inhibitor drug, Entresto, for the treatment of heart failure. This drug has been shown to reduce the risk of hospitalization and death in patients with heart failure.
-
In November 2020, Pfizer and BioNTech announced the results of their clinical trial of the COVID-19 vaccine, which showed that it was 95% effective. Pfizer is a leading producer of ACE inhibitors, and the success of the COVID-19 vaccine has been a major development for the company.
Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Scope
The Angiotensin Converting Enzyme (ACE) inhibitors market is segmented on the basis of product type, drug, dosage form, application and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product Type
- Dicarboxylate-Containing Agents
- Phosphonate-Containing Agents
- Sulfhydryl-Containing Agents
Drug
- Lisinopril
- Ramipril
- Enalapril
- Benazepril
- Fosinopril
- Captopril
- Moexipril
- Others
Dosage Form
- Oral Tablet
- Oral Solution
Application
- Heart Failure
- Hypertension
- Diabetes
- Heart Attack
- Chronic Kidney Disease
- Others
Distribution Channel
- Retail Pharmacy
- Hospital Pharmacy
- E-Commerce Websites
- Online Drug Stores
Angiotensin Converting Enzyme (ACE) Inhibitors Market Regional Analysis/Insights
The Angiotensin Converting Enzyme (ACE) inhibitors market is analysed and market size insights and trends are provided by country, product type, drug, dosage form, application and distribution channel as referenced above.
The countries covered in the Angiotensin Converting Enzyme (ACE) inhibitors market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the Angiotensin Converting Enzyme (ACE) inhibitors market because of the strong base of healthcare facilities, strong presence of major players in the market, increases cases of cardiovascular diseases among the population and rising number of research activities in this region.
Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, rise in healthcare facilities, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The Angiotensin Converting Enzyme (ACE) inhibitors market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for Angiotensin Converting Enzyme (ACE) Inhibitors Market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Angiotensin Converting Enzyme (ACE) Inhibitors Market. The data is available for historic period 2010-2020.
Competitive Landscape and Angiotensin Converting Enzyme (ACE) Inhibitors Market Share Analysis
The Angiotensin Converting Enzyme (ACE) inhibitors market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Angiotensin Converting Enzyme (ACE) Inhibitors market.
Some of the major players operating in the Angiotensin Converting Enzyme (ACE) inhibitors market are:
- Novartis AG (Switzerland)
- Pfizer Inc. (U.S.)
- Merck & Co. (U.S.)
- AstraZeneca (UK)
- Sanofi (France)
- Boehringer Ingelheim (Germany)
- GlaxoSmithKline (U.K.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Lupin Limited (India)
- Cipla (India)
- Torrent Pharmaceuticals Ltd. (India)
- Sun Pharmaceutical Industries Ltd. (India)
- Dr. Reddy's Laboratories Ltd. (India)
- Cadila Healthcare Limited (India)
- Macleods Pharmaceuticals Limited (India)
- Zydus Cadila (India)
- Mylan (US)
- Sandoz (Germany)
- Accord Healthcare (U.K.)
- Apotex (Canada)
SKU-